Optic IconOptic Logo
|
SearchCollectionsBenchmarks
Clinical trial

Single-cell Landscape of BALF in Patients With Severe ARDS and CARDS: an Analysis of the Effectiveness of Steroid Therapy and a Comparison Between COVID-19 ARDS and ARDS From Other Etiologies

ID
Name
Covid20230601
Description
The goal of this observational study is to learn about the effect of steroid therapy in patients with COVID-19 ARDS. The main questions it aims to answer are: * Differences between patients with COVID-19 ARDS before and after steroid treatment in BALF single cell landscape, as well as patients with different prognosis. * Differences between COVID-19 and non COVID-19 ARDS patients in BALF single cell landscape. Participants will Choose whether to use or not to utilize steroid treatment based on conditions.
Trial arms
Trial start
2022-09-24
Estimated PCD
2023-02-09
Trial end
2023-03-15
Status
Completed
Treatment
steroid
Moderate- or high-dose steroids
Arms:
COVID-19 with steroid, non-COVID-19 with steroid
Size
8
Primary endpoint
single-cell analysis in BALF before treatment
before treatment in ICU
single-cell analysis in BALF after treatment
After treatment in ICU for 1-4 weeks
Eligibility criteria
Inclusion Criteria: * Severe ARDS patients Exclusion Criteria: * None
Protocol
{'studyType': 'OBSERVATIONAL', 'patientRegistry': False, 'designInfo': {'observationalModel': 'COHORT', 'timePerspective': 'PROSPECTIVE'}, 'bioSpec': {'retention': 'SAMPLES_WITH_DNA', 'description': 'BALF'}, 'enrollmentInfo': {'count': 8, 'type': 'ACTUAL'}}
Updated at
2023-07-06

1 organization

1 drug

2 indications

Organization
Peking Union Medical College Hospital
Drug
prednisone
Indication
Acute Respiratory Distress Syndrome
Indication
COVID-19